Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks.
Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.